EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Chiral Materials for the Recognition and Inhibition of Amyloid‐β Aggregation

Zixuan Zhang, Kunyi Wang, Xuefan Guo, Guoyang Zhang, Yulong Jin iD, Zhuo Wang iD

Advanced Healthcare Materials · 08.11.2026

DOI: 10.1002/adhm.71957 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advanced Healthcare Materials, online erschienen am 08.11.2026. Verfasst von Zixuan Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Chemical Resource Engineering, College of Chemistry, Beijing University of Chemical Technology, Beijing, China. Die Arbeit nennt 123 Literaturangaben. Gefördert von: National Natural Science Foundation of China, State Key Laboratory of Natural and Biomimetic Drugs, Interdisciplinary Research Center of Beijing University of Chemical Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Abnormal aggregation of amyloid‐β (Aβ) peptides is a central pathological event in Alzheimer's disease (AD), closely associated with neurotoxicity and disease progression. The development of molecules or materials with high selectivity and affinity toward Aβ aggregates constitutes an essential component for the early diagnosis and intervention of AD. Aβ peptides, composed of homochiral amino acids, undergo intermolecular β‐sheet assembly to form supramolecular chiral aggregates, providing a structural basis for chirality‐sensitive recognition. Therefore, chiral materials have attracted significant attention in Aβ aggregates recognition and regulation. Previous reviews have examined different types of chiral materials for the inhibition of Aβ aggregation, including chiral small molecules, amino acids, peptides, and various chiral interfaces or nanomaterials. The present review organizes reported chiral materials according to three intervention strategies for modulating Aβ aggregation: conformation‐locking, self‐assembly‐induced remodeling, and multifunctional intervention. We summarize representative materials in each category, along with the corresponding design principles and modulation performance toward Aβ aggregation. Current challenges and potential directions for the development of chiral therapeutics for AD are also discussed.

Schlagwörter

Stichwörter der Autor:innen

Alzheimer's diseaseAβ aggregation inhibitionamyloid‐βchiral materials

Autor:innen und Institutionen

  • State Key Laboratory of Chemical Resource Engineering, College of Chemistry, Beijing University of Chemical Technology, Beijing, China.
  • Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.

ORCID-Profile: Yulong Jin, Zhuo Wang

Förderung

  • National Natural Science Foundation of China
  • State Key Laboratory of Natural and Biomimetic Drugs
  • Interdisciplinary Research Center of Beijing University of Chemical Technology
  • Fundamental Research Funds for the Central Universities

Zitieren

APA

Zhang, Z., Wang, K., Guo, X., Zhang, G., Jin, Y., & Wang, Z. (2026). Chiral Materials for the Recognition and Inhibition of Amyloid‐β Aggregation. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.71957

Vancouver

Zhang Z, Wang K, Guo X, Zhang G, Jin Y, Wang Z. Chiral Materials for the Recognition and Inhibition of Amyloid‐β Aggregation. Advanced Healthcare Materials. 2026. doi:10.1002/adhm.71957

BibTeX
@article{Zhang2026,
  author = {Zhang, Zixuan and Wang, Kunyi and Guo, Xuefan and Zhang, Guoyang and Jin, Yulong and Wang, Zhuo},
  title = {Chiral Materials for the Recognition and Inhibition of Amyloid‐β Aggregation},
  journal = {Advanced Healthcare Materials},
  year = {2026},
  doi = {10.1002/adhm.71957}
}
Kostenlos starten →